Edition:
United Kingdom

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

84.55USD
6:43pm BST
Change (% chg)

$-1.35 (-1.57%)
Prev Close
$85.90
Open
$85.68
Day's High
$86.19
Day's Low
$84.44
Volume
210,803
Avg. Vol
424,978
52-wk High
$106.69
52-wk Low
$79.15

About

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $16,617.19
Shares Outstanding(Mil.): 175.27
Dividend: --
Yield (%): --

Financials

  BMRN.OQ Industry Sector
P/E (TTM): -- 29.30 32.55
EPS (TTM): -1.02 -- --
ROI: -5.48 14.23 13.82
ROE: -7.41 15.46 15.24

BioMarin says data shows hemophilia gene therapy effects could wane

BioMarin Pharmaceutical Inc said on Tuesday early trial data for its gene therapy for hemophilia A suggested the one-time infusion's effect on some patients' bleeding disorders would last eight years.

28 May 2019

UPDATE 3-BioMarin says data shows hemophilia gene therapy effects could wane

May 28 BioMarin Pharmaceutical Inc said on Tuesday early trial data for its gene therapy for hemophilia A suggested the one-time infusion's effect on some patients' bleeding disorders would last eight years.

28 May 2019

BRIEF-BioMarin Says Payers Unlikely To Accept Price Equivalent To Over 5 Years Of Standard Treatment Costs For Hemophilia Gene Therapy

* BIOMARIN CEO SAYS BELIEVES ONCE HEMOPHILIA GENE THERAPY IS APPROVED CO WILL BE IN 'PRETTY GOOD SHAPE' FOR DISCUSSION ON PRICE WITH PAYERS BASED ON FIVE YEARS OF COSTS, SIMILAR TO NOVARTIS

28 May 2019

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

11 Feb 2019

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK, Feb 11 Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

11 Feb 2019

Earnings vs. Estimates